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The ability of natural killer (NK) cells to
kill virus-infected cells depends on the
presence of ligands for activation recep-
tors on the target cells. We found the
presence of few, if any, NKp30 and NK46
ligands on T cell blasts infected with HIV,
although NKp44 ligands were found on
infected cells. HIV does induce the NKG2D
ligands ULBP-1, -2, and -3. These ligands
are involved in triggering NK cells to kill
autologous HIV-infected cells, because
interfering with the interaction between
NKG2D, but not NKp46, on NK cells and
its ligands on HIV-infected cells drasti-
cally reduced the lysis of infected cells.
Interfering with the binding of the NK-cell
coreceptors NTB-A and 2B4 to their li-
gands also decreased destruction by NK
cells. The coreceptor ligands, NTB-A and
CD48, were also found to be down-
regulated during the course of HIV infec-
tion. Thus, ligands for NK-cell receptors
are modulated during the course of HIV
infection, which may greatly alter NK cells’
ability to kill the infected cells. (Blood.
2007;110:1207-1214)
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Introduction
NK cells are a distinct subset of cytotoxic lymphocytes that are an
important first line of defense against several viruses that recognize
and destroy infected cells without prior sensitization to viral
antigens. The key role that NK cells play in protecting against
certain viruses in vivo was initially highlighted in studies of mice
depleted of NK cells and infected with mouse hepatitis virus,
murine cytomegalovirus, and vaccinia virus.1
In humans, disseminated, life-threatening herpes virus infections
occur in patients with NK-cell deficiencies.2 Moreover, low or dysfunc-
tional NK-cell activity is associated with frequent herpes virus infec-
tions.3,4 The importance of NK-cell responses in controlling viruses is
underscored by the observation that many viruses (eg, herpes, adeno-,
papilloma, and hepatitis viruses) have developed mechanisms to thwart
NK-cell responses.5 At this time, little is known about how HIV triggers
NK cells to kill infected cells and whether the virus has developed
mechanisms to prevent NK-cell–mediated clearance.
Unlike virus-infected cells, normal cells are protected from
NK-cell destruction because major histocompatibility complex
class I molecules (MHC-I) interact with inhibitory receptors
(iNKR) present on NK cells.6-8 However, when viruses down-
modulate MHC-I on infected cells to avoid virus-specific CTL
recognition, infected cells can be destroyed by NK cells because
infected cells lack the ligands that bind the NK-cell iNKR.7,9
Three major families of the iNKR receptors that interact with
different MHC-I on target cells modulate NK cells. The first family
of iNKR receptors is designated killer immunoglobulin (Ig)-like
receptors (KIR), whose members have various numbers of Ig
domains and ligand specificities.10,11 KIR with 2 Ig domains
(KIR2DL1, -2, and -3, also known as CD158a and -b) bind to
different alleles of human leukocyte antigen C (HLA-C) mol-
ecules.7 KIR with 3 Ig domains (KIR3DL1) recognize different
alleles of HLA-B and HLA-A (ie, HLA-Bw4 serotypes) mol-
ecules,12 and a homodimer of KIR3DL2 binds specific haplotypes
of HLA-A molecules.13 The second family of iNKR receptors on
NK cells is a lectin-like heterodimer consisting of CD94 associated
with NKG2A/B, a molecule that binds to HLA-E, a nonclassic
MHC-I. HLA-E presents leader peptides of HLA-A, -B, and -C on
the cell surface.14,15 The last family of iNKR receptors, designated
Ig-like transcripts-2, recognizes multiple HLA types.16 Even though
the iNKR receptors differ in specificity, they all contain immunore-
ceptor tyrosine-based inhibitory motifs (ITIMs) in their cytoplas-
mic regions.16-18 The ITIMs function to recruit and lead to the
activation of inhibitory phosphatases, such as Src-homology do-
main-containing tyrosine phosphatases (SHP)-1 and SHP-2.19
HIV-infected cells down-modulate MHC-I,20 and NK cells kill
cells with low levels of MHC-I.9 Thus, it follows that HIV-infected
cells should be susceptible to NK-cell–mediated killing. However,
we have demonstrated that peripheral blood NK cells cannot kill
HIV-infected, autologous T-cell blasts efficiently despite down-
modulation of MHC-I.21 Cohen et al22 showed that selective
down-regulation of MHC-I by HIV renders the infected cells
resistant to NK-cell killing, and, because the HLA-C and -E
remaining on the cell surface trigger iNKR, protection of the
infected cells results. We20 and others23-26 have observed that,
remarkably, HLA-C and -E iNKR are only expressed on a subset of
NK cells. Therefore, we reasoned that HLA-C and -E prevent
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some, but not all, NK cells from destroying HIV-infected cells. In
support of this idea, we demonstrated that NK cells lacking HLA-C
and -E iNKR kill autologous HIV-infected T cells.20 Because
HIV-infected CD4-positive (CD4) T cells are killed by NK cells
regardless of HLA-C and -E presence, HLA-C and -E may not be
solely responsible for restraining the response.
Lack of, or impaired expression of, MHC-I is not sufficient to
account for killing by NK cells.27 Engagement of activating
receptors on infected cells is required to trigger NK cells to kill.
A variety of surface receptors can induce NK-cell activation. The
Ig-like domain containing natural cytotoxicity receptors (NCR)
NKp30, NKp44, and NKp46, and the C-type lectin NKG2D
receptor, are described as the major NK-cell–activating receptors.28
It is thought that triggering NK-cell activation through NKG2D
and the NCR can be regulated after engagement of iNKR,29-32
although the strength of the activating signal may overcome the
effects of iNKR engagement.27
The cellular ligands for human NCR are not known at this time;
however, influenza hemagglutinin has been identified as a viral
ligand for the NKp46 receptor.33 In contrast, human NKG2D
ligands consist of 2 classes of MHC-I like molecules: human
cytomegalovirus UL-16 binding proteins (ULBP) and MHC-I
related chain (MIC). These molecules are expressed only on
“stressed” cells upon DNA damage and replication inhibition-
induced DNA repair pathways,34 and thus, signal NK-cell–
mediated destruction of the stress-ligand bearing cells.
In addition to the NCR and NKG2D, another set of NK-
cell–activating receptors has been identified that are categorized as
coreceptors because of their ability to amplify NK-cell cytotoxicity
when triggered along with a major activating receptor.35 Both the
CD244/2B4 receptor and the NK-T-B cell antigen (NTB-A) are
members of the CD2 subfamily of receptors, and their ligands have
been identified as CD4836 and NTB-A itself, respectively.37,38
Previous studies have shown that certain lymphoblastic leukemias
are able to down-regulate the expression of CD48 and NTB-A,
thereby escaping destruction by NK cells.39
Although HIV-infected cells can be killed by NK cells lacking
iNKR to HLA-C and -E, it remains to be determined what triggers
the NK cells to kill HIV-infected cells. Here we determined
whether the ligands for NCRs and NKG2D, as well as the ligands
for the NK-cell coreceptors, NTB-A and 2B4, on HIV-infected
cells are important in triggering NK cells to kill the infected cells.
In addition, we determined whether HIV modulates these mol-
ecules on infected cells.
Materials and methods
HIV infection of CD4 T cells
Peripheral blood was obtained from healthy HIV seronegative donors after
informed consent was obtained in accordance with the Declaration of
Helsinki and the policies of the Institutional Review Board for the
protection of human subjects at SUNY Upstate Medical University,
Syracuse, NY, and Rush University Medical Center, Chicago, IL. CD4 T
cells were obtained from peripheral blood mononuclear cells and stimulated
with phytohemagglutinin as described previously.21 CD4 T-cell blasts
were infected with 103 50% tissue culture infective dose (TCID50) (Figure 7
only) or 104 TCID50 of either of the R5 strains, HIV-1SF162 or HIV-1SF128A,
by spin-inoculation as described previously40 or spun with medium as an
uninfected control. Five to 7 days after infection, cells were used in
cytotoxicity assays or prepared for flow cytometric analysis.
Antibodies
The mouse antihuman CD4, CD48, and MICA/B antibodies were pur-
chased from BD Biosciences (La Jolla, CA), and the anti-NTB-A antibody
Figure 1. Expression of NKp30 or NKp46 ligands on HIV-infected primary T cells. (A) The COS-7 cell line was stained with either soluble NKp30-Fc or NKp46-Fc fusion
proteins followed with goat antihuman secondary reagent or the secondary reagent alone. (B) Uninfected and (C) HIV-1SF162–infected CD4 T cells were stained with soluble
NCR as in panel A, fixed and permeabilized, and stained with mouse anti-HIV-1 p24 monoclonal antibodies and rabbit antimouse secondary reagent. Histograms were gated
on 104 viable (panels A,B) or 104 HIV-1 p24 Ag cells (panel C). Dot plots shown are of 3  104 cells in the viable gate from cultures of T-cell blasts infected with HIV-1SF162
(panels D,E) and HIV-1SF128A (panels F,G), and the numbers represent the percentage of viable cells within each quadrant. Data are representative of 3 separate studies.
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used for surface staining was purchased from Biolegend (San Diego, CA).
The soluble fusion proteins of NKp30, NKp44, NKp46, and NKG2D
receptors with the Fc portion of human IgG and mouse antihuman ULBP-1,
-2, or -3 antibodies were obtained from R&D Systems (Minneapolis, MN).
The following monoclonal antibodies were a kind gift from Dr A. Moretta
(University of Genoa, Genoa, Italy): MA127 and ON56 (IgG1 and IgG2b
isotypes, respectively, anti-NTB-A antibody), PP35 and CO54 (IgG1 and
IgM isotypes, anti-2B4 antibody), and BAT221 (IgG1, anti-NKG2D
antibody). Allophycocyanin (APC) and fluorescein isothiocyanate (FITC)-
conjugated goat antihuman IgG Fc-specific antibodies were obtained from
Jackson ImmunoResearch Laboratories (West Grove, PA). FITC-conju-
gated rabbit antimouse IgG Fc-specific antibodies were from Dako
Colorado (Fort Collins, CO). The 2 anti-HIV-1 p24 monoclonal antibodies
used for intracellular flow cytometry staining were obtained from the
National Institutes of Health AIDS Research and Reference Reagent
Program (Germantown, MD). The human monoclonal antibody clone
71-31 was deposited by Dr S. Zolla-Pazner,41 and the mouse monoclonal
antibody clone AG3.0 by Dr J. Allan.42 The mouse anti-HIV-1 p24
monoclonal antibody, KC57, was purchased from Beckman Coulter
(Fullerton, CA). See Figure S1 (available on the Blood website; see the
Supplemental Materials link at the top of the online article) for details of
the staining patterns of various clones of anti-HIV-1 p24 antibodies.
Staining and analysis of uninfected and HIV-infected T-cell blasts
for ligands of NK-cell activation receptors and coreceptors
Uninfected and HIV-infected CD4 T-cell blasts were washed 3 times with
Ca2/Mg2-free phosphate-buffered saline with 2% fetal bovine serum and
0.1% NaN3 (flow buffer). After the final wash, 106 of either uninfected or
HIV-infected CD4 T-cell blasts in flow buffer at a concentration of 107/mL
were stained with titered concentrations of soluble fusion proteins or
monoclonal antibodies for 20 minutes at 4°C. After washing samples twice
with flow buffer, the cells were stained with the appropriate fluorochrome-
conjugated secondary reagents, washed twice in flow buffer and fixed and
permeabilized as described previously.21 After perm-fixing, cells were
stained with either human or mouse anti-HIV-1 p24 antibody as described
previously.20,21 Viable uninfected and/or HIV-p24 Ag-positive (Ag) cells
were acquired using a LSR II flow cytometer (BD Biosciences, San Jose,
CA). Acquired samples were analyzed using the Cellquest program (BD
Biosciences) or FlowJo (Treestar, Ashland, OR).
Cytotoxicity assay
Target cells for 51Cr release assays were prepared by depletion of CD4 T
cells from HIV-infected cells as described previously.20 Purity of the
infected cells after depletion was less than 5% CD4 and CD4-negative
(CD4) cells were more than 95% HIV-1 p24 Ag as determined by flow
cytometric analysis (see Figure S2). NK cells were obtained from the same
donors who provided CD4 T cells for our studies using immunomagnetic
bead isolation with anti-CD56 antibody coupled to magnetic beads (Stem
Cell Technologies, Vancouver, BC, Canada) as described previously.20
CD56-positive (CD56) cells were depleted of CD3-positive (CD3) cells
using anti-CD3 antibody coupled to magnetic beads according to the
manufacturer’s instructions (Dynal, Brown Deer, WI) and rested overnight
before use in cytotoxicity assays. NK cells were not treated with cytokines
at any time. Saturating concentrations (10 g/mL) of specific monoclonal
antibodies blocking NK-cell receptors were added for 30 minutes at 4°C
before and at 37°C during the cytotoxicity assays. Determination of
NK-cell killing of HIV-infected cells was done using the 51Cr release assay
as described previously.20
Results
Determining the expression of ligands for natural cytotoxicity
receptors on HIV-infected cells
Because triggering natural cytotoxicity receptors (NCR) on NK cells
leads to destruction of NCR ligand-expressing target cells,43,44 we
wanted to determine whether HIV-infected CD4 T cells expressed the
NKp30 and NKp46 ligands. For this purpose, we stained the surface
of primary CD4 T cells infected with 2 different strains of
HIV-1 and uninfected CD4 T cells with soluble human
NKp30-Ig and NKp46-Ig fusion proteins. To detect cells
possessing virus, we stained for intracellular HIV-1 p24 Ag. As a
positive control for detecting NCR ligands, we used NKp30-
positive (NKp30) and NKp46-positive (NKp46) cell lines as
control.45 Although NKp30 and NKp46 ligands are detected on
the surface of the cell lines COS-7 (Figure 1A) and 293T (data
not shown), they were absent on uninfected CD4 T cells
(Figure 1B). Only a small percentage (6.97% and 4.39%,
respectively) of HIV-1SF162–infected cells expressed NKp30 and
NKp46 ligand (Figure 1C-E). Cells infected with the HIV-
1SF128A strain did not express the NKp30 and NKp46 ligands
(Figure 1F,G).
Recent studies demonstrated that CD4 T cells from subjects
infected with HIV express the NKp44 ligand.46 In the present study, we
wanted to determine whether HIV-infected CD4 T cells expressing
Figure 2. Expression of NKp44 ligands on HIV-infected primary T cells.
(A,C) uninfected and (B,D) HIV-1SF162– or HIV-1SF128A–infected CD4 T cells
stained with soluble NKp44/IgG Fc fusion protein and goat antihuman secondary reagent
followed by intracellular staining with mouse anti-HIV-1 p24 antibodies. Dot plots shown
are of 3 104 cells in the viable gate from cultures of T-cell blasts infected with HIV, and
the numbers represent the percentage of viable cells within each quadrant. (E) The
percentage of HIV-1 p24 Ag ( ) and p24 Ag (———) infected cells that are NKp44
ligand-positive. Data are representative of 3 separate studies.
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virus possess the NKp44 ligand. To demonstrate the presence of NKp44
ligand, we stained HIV-infected and uninfected CD4 T cells with an
NKp44-Ig fusion protein. We also stained cells for intracellular HIV-1
p24 Ag. Figure 2A,C demonstrate limited expression of NKp44 ligand
on uninfected CD4 T cells (0.28% of CD4 cells). However, when
infected with HIV-1SF162, CD4 T cells express NKp44 ligands in
33.93% of the cells (Figure 2B,E). Infection with another HIV
strain, HIV-1SF128A, also induced NKp44 ligand on the cells
(23.34% [Figure 2D]). These studies demonstrate that HIV-
infected cells express little, if any, NKp30 and NKp46 ligands,
although they did express NKp44 ligands.
HIV-infected cells express the NKG2D ligands ULBP-1, -2, and -3
NKG2D, an activation receptor on NK cells, is capable of
triggering NK cells to kill target cells expressing its ligands.47 To
determine whether HIV-infected cells express the ligands for
NKG2D, we stained cells with soluble NKG2D-Ig fusion protein.
We also stained cells for intracellular HIV-1 p24 Ag. As demon-
strated in Figure 3A,E, NKG2D ligands are present on the infected
cell surface. These same ligands are absent on uninfected CD4 T
cells (Figure 3B). NKG2D ligands are evident on the infected cells
expressing detectable HIV-1 p24 antigen (Figure 3D,F), but few are
found on the HIV-1 p24-negative population (Figure 3C). Thus,
NKG2D ligands are induced on HIV-infected cells containing
detectable HIV antigen.
Human NKG2D ligands consist of the MHC-I like molecules
ULBP-1, -2, and -3, as well as MIC-A and -B.48 We determined
which ligands are present on HIV-infected cells. Antibodies
directed to the various ULBP and MIC molecules were used to
detect specific NKG2D ligands on infected cells. Figure 4A-C
demonstrates the presence of all 3 ULBPs on HIV-1SF162-
infected cells. Neither MICA nor MICB is present on HIV-
infected cells (Figure 4D-F), but can be seen on HeLa cells.
Thus, HIV induces ULBP-1, -2, and -3 but not MICA or MICB
on infected CD4 T cells.
Ligands for NKG2D trigger NK cells to kill HIV-infected cells
Because HIV-infected cells express NKG2D ligands, we wanted to
determine whether the ligands trigger NK cells to kill HIV-infected
cells. For this purpose, we evaluated the ability of NK cells to
destroy autologous HIV-infected cells (CD4/HIV-1 p24 Ag) in a
4-hour 51Cr release assay in the presence of interfering antibodies
to NKG2D. As shown in Figure 5, we were able to significantly
decrease (P  .05) the ability of NK cells to kill HIV-infected cells
when NKG2D’s ability to bind to its ligands was blocked. The
specificity of this interaction is confirmed; blocking NK cells with
an anti-NKp46 monoclonal antibody did not significantly reduce
killing (Figure 5D), because NKp46 ligands are not expressed
on HIV-infected cells (Figure 1C-E). Thus, NKG2D ligands
present on HIV-infected cells are able to induce the cytotoxic
response of NK cells.
NTB-A and CD48 trigger the killing of autologous infected CD4
cells by NK cells and are down-modulated during
the course of HIV-1 infection
Both NTB-A and 2B4 serve as coreceptors during NK-cell activation
and thus augment NK-cell killing when one of the major NK-cell
receptors is also triggered.28 NTB-A is triggered through homophilic
binding, whereas 2B4 recognizes the GPI-linked protein CD48. Both of
these ligands are present on CD4 cells. Because we found
NKG2D ligands on HIV-infected cells (Figures 3-4), we investi-
gated the possibility that NTB-A and CD48 also serve as
coactivating ligands on infected CD4 cells to trigger NK-cell–
mediated cytotoxicity. HIV-infected cells (CD4/HIV-1 p24
Ag) were used as targets in a 4-hour 51Cr release assay using
NK cells treated with either an isotype control antibody or
masked with anti–NTB-A or anti-2B4 monoclonal antibodies as
effectors. A significant (P  .05) decrease in target cell destruc-
tion was detected after masking of the NK-cell coreceptors,
indicating that NK-cell killing of autologous HIV-infected
blasts depends on NTB-A and 2B4 (Figure 6).
Figure 3. CD4 T-lymphocytes infected
with HIV-1 express NKG2D ligands. CD4
T cells (B,F) uninfected or (A,C,D) infected
with HIV-1SF162 or (E,F) HIV-1SF128A were
stained with NKG2D/IgG Fc fusion proteins
and goat antihuman secondary reagent fol-
lowed by staining with mouse anti–HIV-1
p24 antibodies. Numbers in the dot plots
represent the percentage of viable cells
within each quadrant. Histograms (panels
B-D) show expression of NKG2D ligand on
uninfected, HIV-1 p24 Ag infected cells and
HIV-1 p24 Ag infected cells, respectively.
(F) The histogram with the dotted line repre-
sents cells stained with secondary antibod-
ies alone, the histogram with the thin line
represents uninfected cells, and the histo-
gram with the bold line represents HIV-1 p24
Ag cells. These are representative of 5
separate experiments.
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Because HIV is able to modulate MHC-I, CD4, and NKG2D
ligand expression on infected target cells, we also investigated the
possibility that the surface levels of NTB-A and CD48 were altered
on virus-infected cells. During infection with 2 R5 strains, both
CD48 (Figure 7A,C,D) and NTB-A (Figure 7B,E,F) are down-
modulated from the cell surface.
Discussion
We demonstrated in this study that, on HIV-infected cells, NKG2D
ligands are responsible for triggering NK cells to kill HIV-infected
cells. The amount of killing of HIV-infected cells by autologous
NK cells varies from donor to donor and ranges from less than 1%
to as high as 30% at an E/T ratio of 10:1 in donors we have tested.
Only studies that show a detectable amount of killing have been
included here. It is noteworthy that although the majority of
CD56, CD3-negative (CD3) NK cells are NKG2D-positive
(NKG2D), there was no correlation between the level of NK-
cell–mediated killing of HIV-infected cells and the percentage of
NK cells that were NKG2D (see Figure S3). In contrast, the
percentage of cells that is double-positive for NKG2D and the
HLA-E binding inhibitory receptor, NKG2A, differs dramatically
among the donors used in this study and corresponds to the level of
killing observed. This is important because HLA-E molecules
remain on the cell surface during HIV infection.20,22 However, it
should be pointed out that other factors besides inhibitory or
activating receptors may come into play with regard to the
variability observed in NK killing of HIV-infected cells, because
there are a wide range of responses even concerning NK-cell
killing of MHC class I negative K562 target cells.20
The NKG2D ligands on HIV-infected cells that trigger NK cells
are ULBP-1, -2, and -3, but not MICA or MICB (Figure 4). All 3
ULBPs are equally likely to stimulate NK cells to kill.49 We show
that the ligands for the NTB-A and 2B4 coreceptors are responsible
for inducing NK-cell killing. We also demonstrate that NCR
ligands are not likely to trigger NK cells to destroy HIV-infected
cells because few if any NCR ligands are expressed on the
infected cell surface.
Ligands for the NCRs NKp30 and NKp46 are expressed on
few, if any, uninfected or HIV-infected T cells (Figure 1). They
are, however, expressed by tumor cell lines (Figure 1A), in
Figure 4. CD4 T-lymphocytes infected with HIV-1
express NKG2D ligands ULBP -1, -2, and -3 but not
MICA or MICB. (Top panels) Uninfected and HIV-
1SF162–infected primary T-cell blasts were stained with
antibodies directed to ULBP-1, -2, and -3, and a rabbit
antimouse secondary reagent followed by intracellular
staining with a monoclonal human anti-p24 antibody.
(Bottom panels) The NKG2D ligands MICA and MICB
were detected using specific antibodies on HIV-1 p24
Ag infected cells and uninfected CD4 T cells. The
HeLa cell line was used as a positive control for MICA
and MICB expression. MFI  mean fluorescent inten-
sity of antibody used for staining the cells. Data are
representative of 3 separate studies.
Figure 5. Interfering with the interaction between NKG2D and its ligands on HIV-infected T cells decreases NK-cell killing of the infected cells. (A,B,D) CD4/HIV-1
p24 Ag HIV-1SF162– or (C) HIV-1SF128A–infected primary T cells were exposed to autologous NK cells treated in the absence ( ) or presence () of anti-NKG2D blocking
monoclonal antibodies or anti-NKp46 blocking monoclonal antibodies (panel D, ) in a 4-hour cytotoxicity assay (*, P  .05; t test). Error bars represent standard deviation of
the mean. Panels A,B, and D are 3 separate donors; panels C and D are from the same donor.
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agreement with results from previous studies.45 As reported
previously, NKp44 ligands are expressed on cells when exposed
to peptides found in HIV-1 gp41 or when exposed to soluble
HIV-1 gp160.46 In fact, a significant percentage of NKp44
ligand was seen on HIV-infected cells exposed to the virus.
However, this up-regulation of ligand does not affect the
cytotoxicity measured, because NKp44 is only expressed on
cytokine-stimulated NK cells50,51 and is not found on the resting
NK cells used in our assays.
Although NCR ligands are not found on HIV-1 p24 Ag cells,
the NKG2D ligands are present on HIV-infected cells. The level of
NKG2D ligand expression is comparable with that found on
previously reported cell lines.32 The expression of NKG2D ligands
was mostly limited to HIV-1 p24 Ag-expressing HIV-infected cells.
This is important with respect to the recognition of HIV-infected
cells by NK cells, in that only HIV-infected cells down-modulate
MHC-I molecules, which, in turn, inhibit NK-cell responses. It
should be pointed out that not all infected cells express NKG2D
ligands, and other NK-cell activation ligands may be involved in
triggering NK-cell cytotoxicity. Moreover, blocking NK-cell kill-
ing was not complete despite interfering with the interaction
between NKG2D and its ligands with blocking antibody (Figure 5).
Although both HLA-C and -E molecules have specific activation
receptors on NK cells, we have ruled out the role of these activating
receptors in triggering NK cells to kill HIV-infected cells in our
previous studies.20 Thus, we endeavor to determine if novel
activating ligands on HIV-infected cells trigger NK cells.
The specific NKG2D ligands expressed on HIV-1 p24 Ag
HIV-infected cells were ULBP 1-3, but not MICA or MICB. This is
in agreement with a recent study, which demonstrated that HIV-
infected primary CD4 T cells express ULBP-1 and -2 but not
MICA on the surface.52 Studies by Molinero et al53 demonstrated
the expression of MICA on 63%-84% of CD4 T cells. We found
no expression of MICA on CD4 T cells, despite the presence of
the antigen on HeLa cells. We used 2 different clones of monoclo-
nal anti-MICA antibody and did not detect this protein on the CD4
T-cell surface (data not shown). Molinero et al53 used polyclonal
anti-MICA rabbit sera rather than monoclonal antibodies. High
fluorescent background levels were detected in cells stained with
normal rabbit sera (11%-32% positive) whereas less than 0.1% of
Figure 6. Preventing the interaction between NK-cell coreceptors and their ligands on HIV-infected cells decreases NK-cell killing of the targets. (A,B) CD4/HIV-1
p24 AgHIV-1SF128A–infected or (C) HIV-1SF162–infected primary T cells were exposed to autologous NK cells treated in the absence (isotype control) or presence of anti-2B4 or
NTB-A blocking monoclonal antibodies in a 4-hour cytotoxicity assay. Panels A through C represent 3 separate experiments involving 3 different donors (*, P  .05; t test). Error
bars represent standard deviation of the mean.
Figure 7. HIV-1 down-modulates NTB-A and CD48 on infected cells. Primary T-cell blasts either were left uninfected or were infected with 103 TCID50 HIV-1SF162 or
HIV-1SF128A. Cells were surface-stained for (A,C,D) CD48, or (B,E,F) NTB-A followed by intracellular staining for the HIV-1 p24 capsid protein using the human 71-31
monoclonal antibody and goat antihuman secondary antibody. Data are representative of at least 3 different experiments with different donors. In panels A and B, the numbers
in the corners of the plot quadrants are the percentage of viable cells that express the specific markers. Histogram representation of all viable cells is shown in panels C through
F ( represents isotype control staining, ——— represents surface staining of viable uninfected cells, and represents surface staining of viable HIV-infected cells).
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PHA-stimulated CD4 cells were positive using mouse isotype
control antibodies in our study. Despite the high level of back-
ground staining with normal rabbit sera, the difference in anti-
MICA staining may be attributable to the absence of IL-2 in the
medium of stimulated cells in the studies by Molinero et al.53 IL-2
(200 U/mL) was present during the stimulation and culture of
CD4 T cells in our studies. Lack of IL-2 during stimulation may
induce cell stress, thereby leading to induction of MICA expression.
We show here for the first time that NKG2D ligands on
HIV-infected cells trigger NK cells to kill in the absence of
antibodies and cytokine exposure. This is surprising because
previous reports have indicated that NKG2D alone may not be able
to trigger “resting” NK cells to kill cell lines and that coreceptors
may be involved in triggering resting NK cells to degranulate.54 For
example, crosslinking NKG2D and 2B4 on unstimulated NK cells
has been shown to increase Ca2 flux and degranulation compared
with either receptor alone.54 We found that the ligands of the
coreceptors 2B4 and NTB-A are found on CD4 T cells. We did not
observe the expression of CRACC or the DNAM ligand CD155 on
CD4 T cells (data not shown).
It is noteworthy that both NTB-A and CD48 are down-
modulated on the surface of HIV-infected cells compared with
uninfected control cells. The suboptimal triggering of 2B4 and
NTB-A together with NKG2D ligands may still be enough to
trigger resting NK cells to kill HIV-infected targets, although it
should be pointed out that killing may not be optimal if the
coreceptor ligand expression was not at the levels found on
uninfected cells.54 One way to evaluate this is to cross-link 2B4 and
NTB-A on NK cells when exposed to HIV-infected cells. The
interactions of all 3 receptors for proper assessment of their
respective contributions to a triggering signal would be desirable.
However, we have been unable to purify a sufficiently large
number of unstimulated NK cells and infected primary CD4 cells
to perform the study.
The presence of NKG2D ligands on the surface of HIV-1 p24
Ag HIV-infected cells, and the absence of these ligands on
uninfected CD4 cells and the HIV-1 p24 Ag compartment of the
HIV-infected cells, indicates that the production of HIV is neces-
sary for the expression of NKG2D ligands. Expression of NKG2D
ligand is dependent on activation of ATM/ATR, which is triggered
by stress from the DNA damage pathway.34 HIV Vpr leads to
activation of ATR.55-57 It is possible that Vpr is responsible for the
expression of NKG2D ligand on infected cells.
If Vpr is indeed involved in NKG2D ligand expression, the
induction of NKG2D ligands on the infected cells would seem
counterproductive to the virus. However, Vpr has the advantage of
inducing G2 arrest and increasing efficient preintegration events in
the host cells and thus provides the virus an advantage in increasing
the production of virions.55,56 The virus seems to offset the
capability of activating NK cells efficiently by down-regulating the
ligands for the 2B4 and NTB-A coreceptors on the infected cell
surface. The decreased expression of CD48 and NTB-A is further
compounded by our earlier observation that HLA-C and -E
expression on infected cells may decrease the ability of some NK-
cell subsets20 to become activated despite NKG2D expression.
Moreover, NK-cell receptors are modulated during the course of
HIV infection.50,58,59 Future studies, using NK cells from
viremic patients with HIV as effector cells to test cytotoxicity
against infected targets will help to demonstrate the in vivo
relevance of the modulation of activating ligands by the virus.
This intricate interplay of surface receptor and ligand modula-
tion seems to enable HIV to avoid the brunt of NK-cell–
mediated immune function.
Acknowledgments
We thank Professor A. Moretta from the University of Genoa,
Genoa, Italy, for providing monoclonal antibodies, and Kelly
Hudspeth for technical assistance.
This work was supported by National Institutes of Health grants
AI16536, AI56923, and AI52809.
Authorship
Contribution: M.B., J.S. and J.G. performed research and analyzed
data. M.F. performed research. D.M. designed research and wrote
the manuscript. J.W. and E.B. designed and performed research,
analyzed data, and wrote the manuscript. M.B. and J.S. contributed
equally to this study.
Conflict-of-interest disclosure: The authors declare no compet-
ing financial interests.
Correspondence: Edward Barker, Department of Immunology
and Microbiology, Rush University Medical Center, 1735 W.
Harrison St., Chicago, IL 60612; e-mail: edward_barker@rush.edu.
References
1. Bukowski JF, Woda BA, Habu S, Okumura K,
Welsh RM. Natural killer cell depletion en-
hances virus synthesis and virus-induced hepa-
titis in vivo. J Immunol. 1983;131:1531-1538.
2. Biron CA, Byron KS, Sullivan JL. Severe herpes-
virus infections in an adolescent without natural
killer cells. N Engl J Med. 1989;320:1731-1735.
3. Lopez C, Kirkpatrick D, Read SE, et al. Correla-
tion between low natural killing of fibroblasts in-
fected with herpes simplex virus type 1 and sus-
ceptibility to herpesvirus infections. J Infect Dis.
1983;147:1030-1035.
4. Gazit R, Garty BZ, Monselise Y, et al. Expression
of KIR2DL1 on the entire NK cell population: a
possible novel immunodeficiency syndrome.
Blood. 2004;103:1965-1966.
5. Lodoen MB, Lanier LL. Viral modulation of NK
cell immunity. Nat Rev Microbiol. 2005;3:59-69.
6. Ciccone E, Pende D, Vitale M, et al. Self class I
molecules protect normal cells from lysis medi-
ated by autologous natural killer cells. Eur J Im-
munol. 1994;24:1003-1006.
7. Moretta A, Biassoni R, Bottino C, et al. Major his-
tocompatibility complex class I-specific receptors
on human natural killer and T lymphocytes. Im-
munol Rev. 1997;155:105-117.
8. Natarajan K, Dimasi N, Wang J, Mariuzza RA,
Margulies DH. Structure and function of natural
killer cell receptors: multiple molecular solutions
to self, nonself discrimination. Annu Rev Immu-
nol. 2002;20:853-885.
9. Huard B, Fruh K. A role for MHC class I down-
regulation in NK cell lysis of herpes virus-infected
cells. Eur J Immunol. 2000;30:509-515.
10. Long EO, Burshtyn DN, Clark WP, et al. Killer cell
inhibitory receptors: diversity, specificity, and
function. Immunol Rev. 1997;155:135-144.
11. Borrego F, Kabat J, Kim DK, et al. Structure and
function of major histocompatibility complex
(MHC) class I specific receptors expressed on
human natural killer (NK) cells. Mol Immunol.
2002;38:637-660.
12. Rojo S, Wagtmann N, Long EO. Binding of a
soluble p70 killer cell inhibitory receptor to HLA-
B*5101: requirement for all three p70 immuno-
globulin domains. Eur J Immunol. 1997;27:568-
571.
13. Pende D, Biassoni R, Cantoni C, et al. The natu-
ral killer cell receptor specific for HLA-A allotypes:
a novel member of the p58/p70 family of inhibi-
tory receptors that is characterized by three im-
munoglobulin-like domains and is expressed as a
140-kD disulphide-linked dimer. J Exp Med. 1996;
184:505-518.
14. Braud VM, Allan DS, O’Callaghan CA, et al.
HLA-E binds to natural killer cell receptors CD94/
NKG2A, B and C. Nature. 1998;391:795-799.
15. Brooks AG, Borrego F, Posch PE, et al. Specific
recognition of HLA-E, but not classical, HLA class
I molecules by soluble CD94/NKG2A and NK
cells. J Immunol. 1999;162:305-313.
16. Colonna M, Navarro F, Bellon T, et al. A common
inhibitory receptor for major histocompatibility
complex class I molecules on human lymphoid
and myelomonocytic cells. J Exp Med. 1997;186:
1809-1818.
HIV MODULATES NK-CELL ACTIVATING LIGANDS 1213BLOOD, 15 AUGUST 2007  VOLUME 110, NUMBER 4
17. Lazetic S, Chang C, Houchins JP, Lanier LL, Phil-
lips JH. Human natural killer cell receptors in-
volved in MHC class I recognition are disulfide-
linked heterodimers of CD94 and NKG2 subunits.
J Immunol. 1996;157:4741-4745.
18. Burshtyn DN, Lam AS, Weston M, Gupta N,
Warmerdam PA, Long EO. Conserved residues
amino-terminal of cytoplasmic tyrosines contrib-
ute to the SHP-1-mediated inhibitory function of
killer cell Ig-like receptors. J Immunol. 1999;162:
897-902.
19. Burshtyn DN, Scharenberg AM, Wagtmann N, et
al. Recruitment of tyrosine phosphatase HCP by
the killer cell inhibitor receptor. Immunity. 1996;4:
77-85.
20. Bonaparte MI, Barker E. Killing of human immu-
nodeficiency virus-infected primary T-cell blasts
by autologous natural killer cells is dependent on
the ability of the virus to alter the expression of
major histocompatibility complex class I mol-
ecules. Blood. 2004;104:2087-2094.
21. Bonaparte MI, Barker E. Inability of natural killer
cells to destroy autologous HIV-infected T lym-
phocytes. Aids. 2003;17:487-494.
22. Cohen GB, Gandhi RT, Davis DM, et al. The se-
lective downregulation of class I major histocom-
patibility complex proteins by HIV-1 protects HIV-
infected cells from NK cells. Immunity. 1999;10:
661-671.
23. Uhrberg M, Valiante NM, Shum BP, et al. Human
diversity in killer cell inhibitory receptor genes.
Immunity. 1997;7:753-763.
24. Pietra G, Semino C, Cagnoni F, et al. Natural
killer cells lyse autologous herpes simplex virus
infected targets using cytolytic mechanisms dis-
tributed clonotypically. J Med Virol. 2000;62:354-
363.
25. Moretta A, Bottino C, Pende D, et al. Identification
of four subsets of human CD3-CD16 natural
killer (NK) cells by the expression of clonally dis-
tributed functional surface molecules: correlation
between subset assignment of NK clones and
ability to mediate specific alloantigen recognition.
J Exp Med. 1990;172:1589-1598.
26. Malnati MS, Lusso P, Ciccone E, Moretta A, Mor-
etta L, Long EO. Recognition of virus-infected
cells by natural killer cell clones is controlled by
polymorphic target cell elements. J Exp Med.
1993;178:961-969.
27. Lanier LL. NK cell recognition. Annu Rev Immu-
nol. 2005;23:225-274.
28. Moretta A, Bottino C, Vitale M, et al. Activating
receptors and coreceptors involved in human
natural killer cell-mediated cytolysis. Annu Rev
Immunol. 2001;19:197-223.
29. Augugliaro R, Parolini S, Castriconi R, et al. Se-
lective cross-talk among natural cytotoxicity re-
ceptors in human natural killer cells. Eur J Immu-
nol. 2003;33:1235-1241.
30. Menier C, Riteau B, Carosella ED, Rouas-Freiss
N. MICA triggering signal for NK cell tumor lysis is
counteracted by HLA-G1-mediated inhibitory sig-
nal. Int J Cancer. 2002;100:63-70.
31. Wischhusen J, Friese MA, Mittelbronn M, Meyer-
mann R, Weller M. HLA-E protects glioma cells
from NKG2D-mediated immune responses in
vitro: implications for immune escape in vivo.
J Neuropathol Exp Neurol. 2005;64:523-528.
32. Pende D, Cantoni C, Rivera P, et al. Role of
NKG2D in tumor cell lysis mediated by human NK
cells: cooperation with natural cytotoxicity recep-
tors and capability of recognizing tumors of non-
epithelial origin. Eur J Immunol. 2001;31:1076-
1086.
33. Mandelboim O, Lieberman N, Lev M, et al. Rec-
ognition of haemagglutinins on virus-infected
cells by NKp46 activates lysis by human NK cells.
Nature. 2001;409:1055-1060.
34. Gasser S, Orsulic S, Brown EJ, Raulet DH. The
DNA damage pathway regulates innate immune
system ligands of the NKG2D receptor. Nature.
2005;436:1186-1190.
35. Moretta L, Moretta A. Unravelling natural killer cell
function: triggering and inhibitory human NK re-
ceptors. EMBO J. 2004;23:255-259.
36. Brown MH, Boles K, van der Merwe PA, Kumar V,
Mathew PA, Barclay AN. 2B4, the natural killer
and T cell immunoglobulin superfamily surface
protein, is a ligand for CD48. J Exp Med. 1998;
188:2083-2090.
37. Flaig RM, Stark S, Watzl C. NTB-A activates NK
cells via homophilic interaction. J Immunol. 2004;
172:6524-6527.
38. Falco M, Marcenaro E, Romeo E, et al. Ho-
mophilic interaction of NTBA, a member of the
CD2 molecular family: induction of cytotoxicity
and cytokine release in human NK cells. Eur J Im-
munol. 2004;34:1663-1672.
39. Pende D, Spaggiari GM, Marcenaro S, et al.
Analysis of the receptor-ligand interactions in the
natural killer-mediated lysis of freshly isolated
myeloid or lymphoblastic leukemias: evidence for
the involvement of the Poliovirus receptor
(CD155) and Nectin-2 (CD112). Blood. 2005;105:
2066-2073.
40. O’Doherty U, Swiggard WJ, Malim MH. Human
immunodeficiency virus type 1 spinoculation en-
hances infection through virus binding. J Virol.
2000;74:10074-10080.
41. Gorny MK, Gianakakos V, Sharpe S, Zolla-
Pazner S. Generation of human monoclonal anti-
bodies to human immunodeficiency virus. Proc
Natl Acad Sci U S A. 1989;86:1624-1628.
42. Simm M, Shahabuddin M, Chao W, Allan JS, Vol-
sky DJ. Aberrant Gag protein composition of a
human immunodeficiency virus type 1 vif mutant
produced in primary lymphocytes. J Virol. 1995;
69:4582-4586.
43. Pende D, Parolini S, Pessino A, et al. Identifica-
tion and molecular characterization of NKp30, a
novel triggering receptor involved in natural cyto-
toxicity mediated by human natural killer cells. J
Exp Med. 1999;190:1505-1516.
44. Sivori S, Vitale M, Morelli L, et al. p46, a novel
natural killer cell-specific surface molecule that
mediates cell activation. J Exp Med. 1997;186:
1129-1136.
45. Arnon TI, Lev M, Katz G, Chernobrov Y, Porgador
A, Mandelboim O. Recognition of viral hemagglu-
tinins by NKp44 but not by NKp30. Eur J Immu-
nol. 2001;31:2680-2689.
46. Vieillard V, Strominger JL, Debre P. NK cytotoxic-
ity against CD4 T cells during HIV-1 infection: A
gp41 peptide induces the expression of an
NKp44 ligand. Proc Natl Acad Sci U S A. 2005;
102:10981-10986.
47. Bauer S, Groh V, Wu J, et al. Activation of NK
cells and T cells by NKG2D, a receptor for stress-
inducible MICA. Science. 1999;285:727-729.
48. Vivier E, Tomasello E, Paul P. Lymphocyte activa-
tion via NKG2D: towards a new paradigm in im-
mune recognition. Curr Opin Immunol. 2002;14:
306-311.
49. Pende D, Rivera P, Marcenaro S, et al. Major his-
tocompatibility complex class I-related chain A
and UL16-binding protein expression on tumor
cell lines of different histotypes: analysis of tumor
susceptibility to NKG2D-dependent natural killer
cell cytotoxicity. Cancer Res. 2002;62:6178-6186.
50. Mavilio D, Benjamin J, Daucher M, et al. Natural
killer cells in HIV-1 infection: dichotomous effects
of viremia on inhibitory and activating receptors
and their functional correlates. Proc Natl Acad Sci
U S A. 2003;100:15011-15016.
51. Vitale M, Bottino C, Sivori S, et al. NKp44, a novel
triggering surface molecule specifically ex-
pressed by activated natural killer cells, is in-
volved in non-major histocompatibility complex-
restricted tumor cell lysis. J Exp Med. 1998;187:
2065-2072.
52. Cerboni C, Neri F, Casartelli N, et al. Human im-
munodeficiency virus-1 nef protein down modu-
lates the ligands of the activating receptor
NKG2D and inhibits natural killer cell-mediated
cytotoxicity. J Gen Virol. 2007;88:242-250.
53. Molinero LL, Fuertes MB, Rabinovich GA, Fain-
boim L, Zwirner NW. Activation-induced expres-
sion of MICA on T lymphocytes involves engage-
ment of CD3 and CD28. J Leukoc Biol. 2002;71:
791-797.
54. Bryceson YT, March ME, Ljunggren HG, Long
EO. Synergy among receptors on resting NK
cells for the activation of natural cytotoxicity and
cytokine secretion. Blood. 2006;107:159-166.
55. Andersen JL, Planelles V. The role of Vpr in HIV-1
pathogenesis. Curr HIV Res. 2005;3:43-51.
56. Zimmerman ES, Chen J, Andersen JL, et al. Hu-
man immunodeficiency virus type 1 Vpr-mediated
G2 arrest requires Rad17 and Hus1 and induces
nuclear BRCA1 and gamma-H2AX focus forma-
tion. Mol Cell Biol. 2004;24:9286-9294.
57. Roshal M, Kim B, Zhu Y, Nghiem P, Planelles V.
Activation of the ATR-mediated DNA damage re-
sponse by the HIV-1 viral protein R. J Biol Chem.
2003;278:25879-25886.
58. Mavilio D, Lombardo G, Benjamin J, et al. Char-
acterization of CD56-/CD16 natural killer (NK)
cells: a highly dysfunctional NK subset expanded
in HIV-infected viremic individuals. Proc Natl
Acad Sci U S A. 2005;102:2886-2891.
59. Fauci AS, Mavilio D, Kottilil S. NK cells in HIV in-
fection: paradigm for protection or targets for am-
bush. Nat Rev Immunol. 2005;5:835-843.
1214 WARD et al BLOOD, 15 AUGUST 2007  VOLUME 110, NUMBER 4
